PRC-4016 (Icosabutate) Phase I Drug-drug Interaction Study
Status:
Completed
Trial end date:
2014-10-01
Target enrollment:
Participant gender:
Summary
The aim of the study is to evaluate the effect of PRC-4016 at steady state on the
pharmacokinetics (PK) of cytochrome P450 (CYP) 3A substrates (midazolam, simvastatin), a
CYP2C9 substrate (omeprazole) and a CYP2C19 substrate (flurbiprofen) in healthy male/female
subjects.